Renin-angiotensin-aldosterone system inhibitors – a realm of confusion in COVID-19 by Lazar, Angela Madalina
 
 
   https://doi.org/10.47108/jidhealth.Vol4.IssSpecial2.125                                          Lazar AM, Journal of Ideas in Health 2021;4(Special 2):389-394 
 
 © The Author(s). 2021 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons 
Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise 
stated. 
  e ISSN: 2645-9248                             Journal homepage: www.jidhealth.com                                       Open Access 
Renin-angiotensin-aldosterone system inhibitors – a realm of confusion 
in COVID-19  
Angela Madalina Lazar 1*
 
Abstract   
 
Currently, there is a persisting dispute regarding the renin-angiotensin-aldosterone-system (RAAS) inhibitors' safety of 
use in COVID-19 pandemics. On one side, RAAS inhibitors appear to determine an overexpression of ACE2, the 
receptor of SARS-CoV-2. Therefore, they could increase the risk of SARS-CoV-2 infection and its degree of severity. 
On the other side, the discontinuation of RAAS leads to cardiovascular decompensation and has been discouraged by 
the major medical societies. Also, large-cohort studies report beneficial or at least neutral effects for the RAAS 
inhibitors in COVID-19 patients. Worldwide, millions of patients receive RAAS inhibitors for the treatment of 
hypertension and other important comorbidities. In this context, knowledge of the exact effect of these medications 
becomes of crucial significance. This paper aims to fill in a gap in the current knowledge and presents a putative 
mechanism by which RAAS inhibitor administration's beneficial results can be explained better. RAAS inhibitors can be 
beneficial, as they counteract the excessive detrimental activation of the classical angiotensin-converting enzyme 
(ACE) axis, decreasing the angiotensin II levels. The angiotensin receptor blockers (ARBs) increase the angiotensin II 
levels, while the angiotensin-converting enzyme inhibitors (ACEI) increase the angiotensin I levels; these substrates 
will compete with the SARS-CoV-2 for the ACE2 binding, decreasing the viral infectivity. In addition, following the 
RAAS inhibitors treatment, the up-regulated ACE2 will cleave these substrates (angiotensin I and II), particularly to 
angiotensin 1-7 that possesses vasodilator, protective effects. 
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Background  
The current COVID-19 pandemic has already made 2,974,642 
deaths globally, as reported by the World Health Organization 
(WHO) on 16th  April 2021 [1]. Although more than one year 
has passed since the initial burst of the SARS-CoV-2 pandemics 
and the associated high rates of infectivity, morbidity, and 
mortality [2], there is still no definitive specific and effective 
therapy for this type of coronavirus infection [3]. Even more, 
because of the SARS-CoV-2 genomic mutations, the 
achievement of a vaccine for all the viral strains becomes 
extremely difficult, and we can face more and more repeated 
COVID-19 pandemics waves [4, 5]. The limitations in the 
prevention and therapeutic management of COVID-19 are 
explainable through the many current gaps existing in our 
knowledge of the SARS-CoV-2 mechanism of infectivity, 
transmissibility, and differences to other previous 
coronaviruses. In this context, it is not surprising to discover 
that the SARS-CoV-2 infection has become a realm of 
controversies, where nothing is for sure yet. The origin and 
transmissibility routes across species are still unclear; even an 
insect-vector-dissemination for SARS-CoV-2 across species 
and other putative types of inter-human transmissibility than 
those already described have been suggested [4]. Also, there is 
insufficient knowledge of the precise protease/sheddase to 
activate the SARS-CoV-2 for host cell entry and the pathogenic 
mechanisms explaining viral cell syncytia formation [4, 6]. The 
exact intervention of the immune system in the SARS-CoV-2 
infection still holds many mysteries, as the titer of antibodies 
developed by the infected individuals is so variable, and the 
protective titer has not been defined yet. Even more, SARS-
CoV-2 appears to hoax the immune cell and even to elicit an 
"antibody-dependent cell entry," as described by some authors 
[7]. In this realm of uncertainties and controversies, a single 
question remains open: when will the pandemics end?  
However, in the absence of an answer, we must find strategies 
to survive, gain valid knowledge on SARS-CoV-2 and develop 
efficient prevention methods and therapies to address future 
putative re-bursts of coronaviruses pandemics [8]. 
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Controversies regarding the RAAS inhibitors  
The COVID-19 pandemics has also brought many concerns and 
contradictory findings from the scientific community regarding 
the possible effects and safety of the renin-angiotensin-
aldosterone system (RAAS inhibitors) (angiotensin-converting 
enzyme inhibitors (ACEI) and angiotensin II receptor blockers 
(ARB)) in SARS-CoV-2 infected patients [9].  It is suspected 
that ACEI and ARB may increase the risk of infection and lead 
to more severe forms of the disease [10-14]. As there are 
millions of patients treated with these medication classes, 
understanding their exact effects in the context of the SARS-
CoV-2 infection becomes crucial. On one side, RAAS 
inhibitors are considered to determine an up-regulation of 
membrane ACE2 receptors that might increase the risk of 
SARS-CoV-2 infectivity in the treated patients (as ACE2 are 
the receptor for the SARS-CoV-2) [12,15-19]. On the other 
hand, RAAS inhibitors increase the angiotensin II levels, with 
apparent undesired effects, as it has vasoconstrictive, pro-
inflammatory, and pro-hypertrophic effects [20]. Following 
ACEI/ARB therapy, the increase in the angiotensin II level is 
secondary, by accumulation, and feedback increases in the renin 
levels and novel production via non-ACE pathways [21].  
     Currently, it is acknowledged that certain categories of 
patients are at increased risk of SARS-CoV-2 infection and of 
developing more severe forms of the disease. Such categories 
are older, hypertensive, male patients, diabetes, chronic kidney, 
and cardiovascular disease. The same categories of patients are 
also known to receive more frequent medication, including 
ACEI/ARBs [18, 19, 22, 23]. Therefore,  understanding the 
exact effects and mechanism of action of RAAS inhibitors 
becomes a matter of particular importance. However, COVID-
19 patients usually present multiple comorbidities. The 
discontinuity of the RAAS inhibitors in COVID-19 patients 
would be detrimental because it would lead to cardiac 
decompensation and death. Therefore, the discontinuity of the 
RAAS inhibitors was not recommended by the important 
medical societies (European Society of Cardiology Council, 
American Heart Association, American College of Cardiology). 
However, their exact role in SARS-CoV-2 infectivity remains 
tenebrous [24-29]. 
 
Findings from the reported studies on the RAAS inhibitors 
effects in COVID-19 patients  
Many results come from Korean studies, as the world’s first de-
identified COVID-19 patient database is Korean [14]. Such an 
example is a large Korean retrospective observational cohort 
study on 7590 patients diagnosed with COVID-19, of which 
1111 patients had RAAS inhibitors medication within six 
months before the infection, and 794 patients served as a 
comparator cohort. The study has shown that the use of RAAS 
inhibitors in COVID-19 patients was not associated with higher 
all-cause mortality when compared to other classes of 
antihypertensive drugs. Also, the study highlighted that 
replacing the RAAS inhibitors with other antihypertensive 
medication may increase the risk of cardiovascular events in 
certain categories of patients (patients with heart failure, 
chronic kidney disease, after acute myocardial infarction) [14]. 
Kim et al. [15] conducted a retrospective nationwide study in 
Korea on a group of 5707 patients with confirmed COVID-19 
(from a cohort of 69793 subjects screened for COVID-19). The 
authors found that the use of ACEI/ARB was not statistically 
associated with poorer outcomes (all-cause mortality, 
respiratory events, need for ICU admission, the necessity for 
mechanical ventilation, the occurrence of sepsis) for COVID-19 
patients when compared to non-users. In fact, on the contrary, 
the COVID-19 patients treated with ACEI/ARB for their 
comorbidities (hypertension, heart disease, renal diseases) had 
better clinical outcomes than the non-users. The ACEI/ARB 
users were more frequent than the non-users older, male 
patients, associating a history of comorbidities such as 
hypertension, hyperlipidemia, diabetes, cardiovascular, or 
kidney disease.  Therefore, the better clinical outcome for the 
RAAS inhibitors users is even more interesting [15]. The 
finding of Kim et al. [15] is surprising as these comorbidities 
are usually associated with poorer outcomes for the COVID-19 
patients [18, 30-33]. Similar beneficial results of RAAS 
inhibitors in COVID-19 have also been reported by other 
studies collecting data from Italy and the United States [10, 34, 
35]. Therefore, the resulting conclusion from some of the 
performed clinical studies is that ACEI/ARB can be beneficial 
for COVID-19 patients with preexisting cardiovascular 
medication. Baral et al. [19] performed a systematic review on 
40 trials selected out of 1031 studies from PubMed and Embase 
(the largest up-to-date). As a result of their extensive analysis, 
the authors reported a lower risk of severe/critical outcomes and 
death in hypertensive ARB/ACEI COVID-19 patients as 
opposed to non-ARB/non-ACEI users [19]. Therefore, the 
systematic review of Baral et al. [19] supports the use of RAAS 
inhibitors in COVID-19 patients. However, the authors of the 
review conclude that the exact role of these medications is still 
insufficiently understood.  
     The limitations of the analyzed studies explain the reserve in 
concern with a clear conclusion; most of them were 
observational, retrospective, with a lack in the randomized 
controlled studies [19]. However, some studies report mixed 
results. For example, an important study conducted on a cohort 
of Veterans with a history of hypertension treated with 
ACEI/ARB for at least two years or with other types of 
medications (control) has found that ACEI use was, in fact, 
significantly associated with a lower risk of a positive SARS-
CoV-2 test compared to non-users and ARB users.  
     Interestingly, the use of ACEI was significantly associated 
with a higher risk of hospitalization and mechanical ventilation 
compared to non-users or ARB users. The study of Li et al. [23] 
showed that neither ACEI nor ARB use was associated with 
increased mortality or other adverse events for the COVID-
treated patients than ACEI/ARB-non-users [23]. However, such 
an extensive study has some limitations: the majority of the 
patients (around 93%) were male; the study did not consider the 
use of diuretics in the previous treatment of the patients and 
other sources of bias/confounder factors. Other studies have not 
described a direct beneficial effect regarding RAAS inhibitors' 
use. However, they reported no significant association between 
using this type of medication and increased susceptibility to 
SARS-CoV-2 infection or worse patient outcomes, arguing 
against ACEI/ARB discontinuation [11, 36, 37]. Nonetheless, 
another study, a randomized trial of 699 patients with moderate- 
and severe forms of COVID-19, with previous ACEI/ARB 
medication showed that ACEI/ARB discontinuation did not 
lead to a worse outcome compared to the group of patients that 
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received a continuous ACEI/ARB administration [13]. 
Altogether, the number of studies describing a neutral effect of 
ACEI/ARB is small [38]. However, no clinical studies reporting 
a significantly detrimental result of RAAS inhibitors in 
COVID-10 patients associating cardiovascular comorbidities 
could be found in the existing literature. Therefore, most of 
these studies' results are contrary to what was previously 
suspected, and the real mechanism by which these medications 
intervene in SARS-CoV-2 infection is only partially 
understood. There are still reports that remain inconclusive [23], 
and even the up-regulation of the ACE2 receptors in RAAS 
users is now questioned. In this regard, some studies have even 
started to question the frequency of the ACE2 overexpression 
after RAAS-inhibitors treatment or require additional evidence 
[18, 39]. Other studies report inconsistent effects, where RAAS 
inhibitors increase, other times decrease, or even do not alter the 
ACE2 expression level [40].  
 
Mechanisms by which RAAS inhibitors could be beneficial   
SARS-CoV-2 uses ACE2 receptors in order to enter the host 
cells. However, SARS-CoV-2 infection determines a 
downregulation of the membrane ACE2 [41] by multiple 
mechanisms. Also, increased angiotensin II levels per se (that 
occur in SARS-CoV-2 infection) appear to lead to an ACE2 
receptor downregulation [40]. SARS-CoV-2 binding to the host 
cells leads to the activation and up-regulation of ADAM-17, an 
enzyme that determines the shedding of the full-length ACE2 
receptors and the release of short, soluble ACE2 into the 
plasma. As a result, a downregulation of the membrane ACE2 
ensues. Also, COVID-19 is associated with an important 
cytokine storm and oxidative stress that activate ADAM-17, 
leading to more ACE2 shedding and a loss in the membrane 
ACE2 receptors [18, 41]. IL-4 and IFN-gamma are known to 
induce repression in the expression of the ACE2 mRNA. The 
decrease in the ACE2 leads to an accumulation of angiotensin II 
(Ag-II). Ag-II will activate the ERK-MAP kinase signaling 
pathway. The consequence will be activating ADAM-17 and a 
sustained feedback loop limiting ACE2 expression on the cell 
membranes. The death of the infected cells is another 
mechanism that contributes to the decrease in the ACE2 by loss; 
this decrease in the ACE2 expression will be followed by an 
unbalanced ACE axis activity [41]. The downregulation of the 
membrane ACE2 receptors is ensured by unbalance between the 
ACE and ACE2 [41]. Therefore, more angiotensin II will act on 
angiotensin II receptors (AT1 receptors) with vasoconstrictive, 
pro-inflammatory, pro-thrombotic, and pro-hypertrophic 
effects. Ag-II is known to induce the activation of nicotine-
amide adenine dinucleotide phosphate oxidase (NADPH) in 
endothelial and smooth muscle vascular cells, increasing the 
generation of reactive oxygen species that lead to cell injury and 
apoptosis. Ag-II also leads to detrimental lung fibrosis; it 
activates the p38 and p42/44 MAPK signaling pathways, 
followed by the proliferation of fibroblasts and lung fibrosis.  
Therefore, a decrease in ACE2 is followed by inflammation, 
cytokine storm, lung, and cardiac impairment [40, 41]. As a 
result, an increase in the ACE2 expression following RAAS 
inhibitors treatment could be beneficial, counteracting the 
excessive and damaging ACE axis with detrimental Ag-II 
accumulation [18, 41]. ACE2 counteracts the effects of ACE as 
it converts the angiotensin II to angiotensin 1-7 (Ag 1-7) that is 
a vasodilator; it also converts angiotensin I to angiotensin 1-9 
[38, 40]. As ACEI decrease the levels of Ag-II, they also 
determine a beneficial decrease in the activation of ADAM-17, 
generation of oxygen free radicals by the lung macrophages, in 
the inflammatory response, the level of pro-inflammatory 
cytokines, the degree of cell injury and fibrosis [18, 40-42]. 
Therefore, RAAS inhibitors can be protective against lung 
injury. Also, as SARS-CoV-2 infection can lead to multiple 
organ injuries, including cardiac, the use of RAAS inhibitors 
could be additionally beneficial, as there are limited alternatives 
of effective cardiovascular medication [18, 41, 42].  
     In fact, the discontinuation of RAAS inhibitors in 
cardiovascular patients appears to increase morbidity and 
mortality among COVID-19 patients [43]. Some authors report 
that the anti-inflammatory effect of the RAAS inhibitors 
appears to be more pronounced in metabolic syndrome and 
aged rats [40]; this suggests a putative, more beneficial effect of 
this medication in more vulnerable groups of patients. It is 
known that ADAM-17 mediated shedding of ACE2 is essential 
for viral entry into the host cells. Therefore, a decrease in 
ADAM-17 activity following RAAS inhibitors treatment can 
reduce viral infectivity. That is why ADAM-17 inhibitors have 
already been proposed as antiviral treatment [40, 42]. Some 
studies also report a decrease in the TMPRSS2 expression 
following the ACEI, but not ARB's treatment. TMPRSS2 
decreased levels can be another explanation for RAAS 
inhibitors' beneficial effects in COVID-19, as TMPRSS2 is an 
important enzyme in SARS-CoV-2 activation. Therefore, a 
decrease in TMPRSS2 will mean a decrease in the host cell 
infection [41]. 
 
Additional putative explanations for the mechanisms that 
underlie the beneficial effects of RAAS inhibitors in 
COVID-19 patients 
Currently, despite the studies mentioned above, the effects and 
the exact mechanism by which ACEI/ARB intervenes in 
COVID-19 patients with cardiovascular diseases are still only 
partially understood. In 2020, Sommerstein et al. [9] launched a 
hypothesis suggesting that the RAAS inhibitors could increase 
the risk for SARS-CoV-2 infection and that of fatal outcomes 
[14, 38]. Since then, the hypothesis has been insufficiently 
opposed by the limited, mostly retrospective, reported studies 
on the effects of RAAS inhibitors in COVID-19.  
     However, the conducted studies describe beneficial or 
neutral effects of this medication in COVID-19. Therefore, 
controversy regarding the effects of RAAS inhibitors in 
COVID-19 still persists. The finding that the ACE function is 
also essential for innate and adaptive immunity, playing a major 
role in fighting against infections and tumors, adds a 
supplementary level of confusion. ACE is expressed on immune 
cells, such as neutrophils and monocyte-macrophages, and was 
shown to play a key role as an important pro-inflammatory 
modulator. Its depletion was associated with an increased 
gravity of infections and tumor progression in mice [44, 45]. 
Therefore, we would expect that ACEI/ARB leads to a worse 
prognostic in COVID-19 patients; however, this “expectation” 
is contradicted by the reported beneficial results of the RAAS 
inhibitors in the COVID-19 patients, as well as reported in 
laboratory studies [19, 40, 42].   
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Author’s viewpoint 
The personal opinion expressed in the current paper is that 
RAAS inhibitors could be beneficial in SARS-CoV-2 disease 
by multiple mechanisms. ACEI and ARB could be beneficial as 
they increase the blood level of angiotensin II and I. The 
angiotensin-converting enzyme inhibitors (ACEI) prevent the 
action of the ACE enzyme that normally cleaves angiotensin I 
and leads to the formation of angiotensin II. Therefore, by 
blockage of the ACE, the potent vasoconstrictor angiotensin II 
levels will decrease while those of the angiotensin I increase. 
There are almost no scientific reports on the biological effects 
of angiotensin I per se. However, it is known to be a substrate 
for ACE2; ACE will cleave angiotensin I to angiotensin 1-9 that 
will act on AT2 receptors, with beneficial effects (vasodilator, 
anti-inflammatory, anti-thrombotic, anti-fibrotic effects). Also, 
the initial decrease in angiotensin II will lead to a feedback 
increase in renin levels followed by elevated levels of 
angiotensin II in patients chronically treated with ACEI [18, 
21].  
     ACE is known to play a role in bradykinin conversion. ACEI 
will prevent this action, resulting in increased levels of 
bradykinin, with vasodilator effects in the treated patients [21, 
22]. However, concerning bradykinin, ACEI could also be 
detrimental, as an increase in bradykinin levels could aggravate 
lung inflammation and contribute to shock development. 
However, by vasodilator action, bradykinin helps in improving 
organ blood flow. That is why it is regarded as protective in the 
case of COVID-19 hypertensive patients. Therefore, for the 
COVID-19 patients having cardiovascular comorbidities, the 
beneficial effects are considered to overpass the potential harm 
[41]. The angiotensin-receptor blockers (ARB) block the action 
of angiotensin II on its AT1 receptors, therefore preventing the 
vasoconstrictive, pro-inflammatory, pro-hypertrophic, and pro-
fibrosis effects of angiotensin II. The levels of angiotensin II 
will increase, but usually, it does not accumulate, as it becomes 
the substrate of other enzymes, such as ACE2. ACE2 converts 
angiotensin II into angiotensin 1-7 that acts on cell Mas 
receptors, with vasodilator, anti-inflammatory, and anti-fibrotic 
effects (opposite to angiotensin II) [18]. In this regard, a 
previous study from 2002 suggests that blocking ACE will 
potentially increase the level of activity of other enzymes 
involved in angiotensin I and bradykinin processing [22]. 
However, the authors did not name ACE2, its existence being a 
recent discovery at that time (in 2000) [46].  
     Anyway, Ferrario et al. have found that ACEI and ARBs 
determine a beneficial increase in ACE2 expression, Ag 1-7 
levels, and decreased Ag-II level [47]. Moreover, long-term 
administration of ACEI is known to increase renin levels and 
associate increased levels of Angiotensin II produced in other 
tissues than the kidney [21]. More angiotensin II will mean 
more substrate for the ACE2. The increased levels of 
angiotensin II/angiotensin I generated by ACEI/ARB 
administration, as natural substrates, will compete with the 
SARS-CoV-2 for the ACE2 binding. As a result, ACE2 
downregulation caused by SARS-CoV-2 binding to ACE2 
receptors will be prevented/reduced, with positive outcomes for 
cardiovascular patients. There will be more ACE2 to cleave its 
natural substrates, angiotensin I and II; such cleavage will 
increase angiotensin 1-7 levels with vasodilator and anti-
inflammatory effects and a decrease in the vasoconstrictive, 
pro-inflammatory and pro-fibrotic effects of angiotensin II. An 
important aspect of being considered is that the SARS-CoV-2 
infection leads to a downregulation of membrane ACE2 
receptors. ACE2 enzyme converts angiotensin II to angiotensin 
1-7 (with vasodilator, anti-inflammatory, and anti-hypertrophic 
effects) and angiotensin I to angiotensin 1-9, counteracting the 
effects of angiotensin II. Therefore, ACE2 downregulation 
would clearly be detrimental. The downregulation of the 
membrane ACE2 would explain why in patients with severe 
forms of COVID disease, angiotensin II levels are increased 
compared with healthy individuals. The increase in the 
angiotensin II levels will have a negative impact on the overall 
course of the disease [48]. In this regard, as ACEI/ARB leads to 
an upregulation of ACE2 expression [12], their final effect 
might be beneficial, contrary to what was originally suspected. 
 
Conclusion  
Worldwide, there are millions of patients treated with RAAS 
inhibitors. Therefore, knowledge of the RAAS inhibitor's 
mechanism of action, usefulness, safety, and effects in the 
context of the SARS-CoV-2 infection becomes of utmost 
importance. Future research should be done to assess the effects 
of  ACEI/ARB on the circulating levels of angiotensin I, 
angiotensin II, angiotensin 1-7, angiotensin 1-9, bradykinin 
levels, membrane ACE2 expression (mRNA for ACE2) at 
different time points during their administration compared to 
ACEI/ARB non-users. An increased level of angiotensin 1-7 
and 1-9 in the ACEI/ARB users would suggest a mechanism of 
action similar to that described by us. However, up to date, most 
of the performed studies have many limitations and are not 
internationally generalizable [11]. Therefore, caution should be 
taken in issuing concluding remarks, as the research remains 
open in the COVID realm of controversies. 
 
Abbreviation  
COVID-19: Coronavirus Disease 19; WHO: World Health 
Organization; SARS-CoV-2: Severe Acute Respiratory 
Coronavirus 2; RAAS inhibitors: Renin-Angiotensin-
Aldosterone Inhibitors; ACEI: Angiotensin-Converting Enzyme 
Inhibitors; ARB: Angiotensin II Receptor Blockers; ACE2: 
Angiotensin-Converting Enzyme 2; ACE: Angiotensin-
Converting Enzyme; Angiotensin II: Ag-II; NADPH: Nicotine-
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